Quarterly ResultMay 14, 2026, 08:22 AM
Cingulate Q1 Net Loss $(9.31)M; Cash $25.9M; Going Concern Doubt
AI Summary
Cingulate Inc. reported a net loss of $(9.31) million for Q1 2026, significantly wider than the $(3.85) million loss in Q1 2025. The company's cash and cash equivalents increased to $25.9 million as of March 31, 2026, primarily due to $21.91 million in net cash provided by financing activities, including common stock issuances. Despite the increased cash, the company continues to incur losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern. The NDA for its lead asset CTx-1301 was accepted with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026.
Key Highlights
- Net loss widened to $(9.31) million in Q1 2026 from $(3.85) million in Q1 2025.
- Cash and cash equivalents increased to $25.9 million as of March 31, 2026.
- Net cash provided by financing activities was $21.91 million in Q1 2026.
- General and administrative expenses surged to $5.74 million from $1.48 million YoY.
- Accumulated deficit reached $(141.69) million as of March 31, 2026.
- NDA for CTx-1301 accepted with PDUFA target action date of May 31, 2026.
- Company faces substantial doubt about its ability to continue as a going concern.